Novo Nordisk A/S (NVO) is in Healthcare, Drug Manufacturers - General, based in Denmark, listed on NYSE. Market cap 168.54B USD. 52-week range 35.12 to 64.16 USD. Trailing P/E 9.3. Data as of 2026-10-09.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The ...